Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Neal I. Lindeman, M.D.

Co-Author

This page shows the publications co-authored by Neal Lindeman and Bruce Johnson.
Connection Strength

0.915
  1. The introduction of systematic genomic testing for patients with non-small-cell lung cancer. J Thorac Oncol. 2012 Dec; 7(12):1767-1774.
    View in: PubMed
    Score: 0.134
  2. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Clin Cancer Res. 2012 Aug 15; 18(16):4406-14.
    View in: PubMed
    Score: 0.130
  3. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol. 2006 Sep 20; 24(27):4517-20.
    View in: PubMed
    Score: 0.087
  4. A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 1):751-8.
    View in: PubMed
    Score: 0.084
  5. Genomic Characterization of de novo Metastatic Breast Cancer. Clin Cancer Res. 2021 02 15; 27(4):1105-1118.
    View in: PubMed
    Score: 0.058
  6. Identifying ERBB2 Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials. JCO Precis Oncol. 2019; 3.
    View in: PubMed
    Score: 0.054
  7. Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight. 2016 11 17; 1(19):e87062.
    View in: PubMed
    Score: 0.044
  8. Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung. J Thorac Oncol. 2013 Nov; 8(11):1434-7.
    View in: PubMed
    Score: 0.036
  9. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2013 Feb; 8(2):179-84.
    View in: PubMed
    Score: 0.034
  10. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res. 2010 Mar 01; 16(5):1561-71.
    View in: PubMed
    Score: 0.028
  11. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res. 2009 Aug 15; 15(16):5216-23.
    View in: PubMed
    Score: 0.027
  12. Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers. Clin Cancer Res. 2008 Nov 01; 14(21):6963-73.
    View in: PubMed
    Score: 0.025
  13. Characterizing the cancer genome in lung adenocarcinoma. Nature. 2007 Dec 06; 450(7171):893-8.
    View in: PubMed
    Score: 0.024
  14. LKB1 modulates lung cancer differentiation and metastasis. Nature. 2007 Aug 16; 448(7155):807-10.
    View in: PubMed
    Score: 0.023
  15. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007 May 18; 316(5827):1039-43.
    View in: PubMed
    Score: 0.023
  16. Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol. 2007 Mar 01; 25(7):760-6.
    View in: PubMed
    Score: 0.022
  17. Epidermal growth factor receptor mutation testing in the care of lung cancer patients. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 2):4403s-4408s.
    View in: PubMed
    Score: 0.022
  18. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res. 2006 Jul 01; 12(13):3908-14.
    View in: PubMed
    Score: 0.021
  19. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst. 2005 Aug 17; 97(16):1185-94.
    View in: PubMed
    Score: 0.020
  20. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004 Jun 04; 304(5676):1497-500.
    View in: PubMed
    Score: 0.018
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.